Reduced CNS exposure of memantine in a triple transgenic mouse model of Alzheimer's disease assessed using a novel LC-MS technique

Journal of Pharmaceutical and Biomedical Analysis

Volumn 85, Issue , 2013, Pages 198-206

  Mehta, Dharmini C ^a   Short, Jennifer L ^a   Nicolazzo, Joseph A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; Blood brain barrier; LC MS; Memantine; Triple transgenic

Indexed keywords

MEMANTINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; BRAIN PERFUSION; CENTRAL NERVOUS SYSTEM; DRUG TRANSPORT; DRUG UPTAKE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALZHEIMER'S DISEASE; BLOOD-BRAIN BARRIER; LC-MS; MEMANTINE; TRIPLE TRANSGENIC;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CHROMATOGRAPHY, LIQUID; DISEASE MODELS, ANIMAL; MALE; MASS SPECTROMETRY; MEMANTINE; MICE; MICE, TRANSGENIC;

EID: 84882717375     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.07.027     Document Type: Article

References (37)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
2. National Institute on Aging Alzheimer's disease fact sheet 2011, http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet.
3. Molinuevo J.L., Llado A., Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. Am. J. Alzheimers Dis. Other Demen. 2005, 20:77-85.
4. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005, 57:173-185.
5. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.
6. Farkas E., Luiten P.G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 2001, 64:575-611.
7. 1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci. Lett. 2006, 401:219-224.
8. Kuhnke D., Jedlitschky G., Grube M., Krohn M., Jucker M., Mosyagin I., Cascorbi I., Walker L.C., Kroemer H.K., Warzok R.W., Vogelgesang S., M.D.R1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-β peptides-implications for the mechanisms of Aβ clearance at the blood-brain barrier. Brain Pathol. 2007, 17:347-353.
9. Nicolazzo J.A., Mehta D.C. Transport of drugs across the blood-brain barrier in Alzheimer's disease. Ther. Deliv. 2010, 1:595-611.
10. Liu W., Bi K., Liu X., Zhao J., Chen X. Cloud-point extraction combined with LC-MS for analysis of memantine in rat plasma. Chromatographia 2009, 69:837-842.
11. Pan R.-N., Chian T.-Y., Kuo B., Pao L.-H. Determination of memantine in human plasma by LC-MS-MS: application to a pharmacokinetic study. Chromatographia 2009, 70:783-788.
12. Toker S.E., Saǧirli O., Çetin S.M., Önal A. A new HPLC method with fluorescence detection for the determination of memantine in human plasma. J. Sep. Sci. 2011, 34:2645-2649.
13. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 2003, 39:409-421.
14. Nicolazzo J.A., Charman S.A., Charman W.N. Methods to assess drug permeability across the blood-brain barrier. J. Pharm. Pharmacol. 2006, 58:281-293.
15. Takasato Y., Rapoport S.I., Smith Q.R. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 1984, 247:484-493.
16. Banks W.A., Morley J.E., Lynch J.L., Lynch K.M., Mooradian A.D. Insulin detemir is not transported across the blood-brain barrier. Peptides 2010, 31:2284-2288.
17. Banks W.A., Niehoff M.L., Zalcman S.S. Permeability of the mouse blood-brain barrier to murine interleukin-2: predominance of a saturable efflux system. Brain Behav. Immun. 2004, 18:434-442.
18. Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation 2001, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory%20Information/Guidances/UCM070107.pdf.
19. Smith Q.R. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. Pharm. Biotechnol. 1996, 8:285-307.
20. Milnerwood A.J., Gladding C.M., Pouladi M.A., Kaufman A.M., Hines R.M., Boyd J.D., Ko R.W., Vasuta O.C., Graham R.K., Hayden M.R., Murphy T.H., Raymond L.A. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65:178-190.
21. Moreau C., Delval A., Tiffreau V., Defebvre L., Dujardin K., Duhamel A., Petyt G., Hossein-Foucher C., Blum D., Sablonnière B., Schraen S., Allorge D., Destée A., Bordet R., Devos D. Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J. Neurol. Neurosurg. Psychiatry 2013, 84:552-555.
22. Dagenais C., Rousselle C., Pollack G.M., Scherrmann J.-M. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J. Cereb. Blood Flow Metab. 2000, 20:381-386.
23. Cattelotte J., Andre P., Ouellet M., Bourasset F., Scherrmann J.M., Cisternino S. In situ mouse carotid perfusion model: glucose and cholesterol transport in the eye and brain. J. Cereb. Blood Flow Metab. 2008, 28:1449-1459.
24. Fromm M.F., Kim R.B., Stein C.M., Wilkinson G.R., Roden D.M. Inhibition of P-glycoprotein mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999, 99:552-557.
25. Huwel S., Lohmann C., Galla H.J. Predicting blood-brain barrier permeability of drugs:evaluation of different in vitro assays. J. Drug Target. 2002, 10:263-276.
26. Murakami H., Takanaga H., Matsuo H., Ohtani H., Sawada Y. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H1022-H1028.
27. Zhao R., Kalvass J., Pollack G. Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique. Pharm. Res. 2009, 26:1657-1664.
28. Tamai I., Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 2000, 89:1371-1388.
29. Park S., Sinko P.J. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 2005, 312:1249-1256.
30. Hartz A.M., Miller D.S., Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-β in a mouse model of Alzheimer's disease. Mol. Pharmacol. 2010, 77:715-723.
31. 1-40 peptides. J. Neurosci. 2009, 29:5463-5475.
32. Mastrangelo M.A., Bowers W.J. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci. 2008, 9:1-31.
33. Zarow C., Barron E., Chui H.C., Perlmutter L.S. Vascular basement membrane pathology and Alzheimer's disease. Ann. NYAcad. Sci. 1997, 826:147-159.
34. Bourasset F., Ouellet M., Tremblay C., Julien C., Do T.M., Oddo S., LaFerla F., Calon F. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. Neuropharmacology 2009, 56:808-813.
35. Zwolinski B.J., Eyring H., Reese C.E. Diffusion and membrane permeability. J. Phys. Chem. 1948, 53:1426-1453.
36. Busch A.E., Karbach U., Miska D., Gorboulev V., Akhoundova A., Volk C., Arndt P., Ulzheimer J.C., Sonders M.S., Baumann C., Waldegger S., Lang F., Koepsell H. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol. Pharmacol. 1998, 54:342-352.
37. Löscher W., Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 2005, 76:22-76.